TRIPTODUR KIT: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Azurity	TRIPTODUR KIT	triptorelin pamoate	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	208956	NDA	Azurity Pharmaceuticals, Inc.	24338-150-20	1 KIT in 1 CARTON (24338-150-20) * 2 mL in 1 VIAL * 2 mL in 1 SYRINGE, GLASS	2017-09-08
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: May 27, 2026

TRIPTODUR KIT Suppliers: Who Manufactures, Supplies, and Distributes the Product Globally?

TRIPTODUR KIT (triptorelin pamoate for prolonged-release suspension; commonly supplied as a kit for administration) is sourced through a limited chain: a drug substance/DP manufacturer, kit assembly and packaging suppliers, and distribution partners that cover each market’s wholesaler, hospital, or specialty pharmacy channel.

What follows is the supplier map you should use for supplier qualification, licensing diligence, and distribution risk review.

Who supplies TRIPTODUR KIT to wholesalers and hospitals?

TRIPTODUR KIT supply typically runs through the sponsor’s commercial supply chain into country-specific wholesalers and institutional distribution. In practice, the “supplier” seen by procurement teams is usually one of these:

Market authorization holder (MAH) / sponsor supplying the national supply under GMP batch release oversight.
Wholesaler/distributor contracted by the MAH or local affiliate for hospital and specialty channel fulfillment.
Contract manufacturer (CDMO) handling drug product manufacture and/or kit assembly, with the MAH importing and distributing.

For supplier qualification, the critical distinction is whether your counterparty supplies:

Kit components and assembled kit (packaging + final kit configuration), or
Bulk DP and kit assembly is done elsewhere, then imported to your jurisdiction.

Which companies manufacture TRIPTODUR (triptorelin) for prolonged-release kits?

TRIPTODUR KIT contains triptorelin pamoate in a prolonged-release injectable kit format. Manufacturer roles split into:

Drug product manufacturer (sterile injection DP / sterile drug product): makes and fills sterile components and final prolonged-release form.
Kit assembly and packaging supplier: assembles the injection kit components (e.g., sterile suspension components, injection device/needles if included, diluent where applicable), performs labeling, packs, and releases for distribution.
Niche sterile fill-finish suppliers: in some markets, DP fill and final assembly may be separated contractually.

Supplier diligence should verify: sites on the finished product’s labeling, batch release location, and whether the “kit” is manufactured at the same site as DP.

What is the Orange Book status of TRIPTODUR KIT, and does it affect supplier availability?

TRIPTODUR is a prescription product based on triptorelin (a GnRH analog). It is not typically evaluated under the FDA Orange Book in the same way as small-molecule generics, because many triptorelin products are not the same as listed generic equivalents with a straightforward Orange Book mapping.

For supplier risk, the more relevant question is regulatory exclusivity and the absence or presence of FDA-listed ANDA approvals for the same kit configuration.

Practical implication for suppliers: where there is no direct ANDA competition for the exact kit configuration, fewer parallel suppliers appear in distribution channels, which concentrates supply dependence on the MAH’s chain.

What patents protect TRIPTODUR KIT and how does this shape who can supply it?

TRIPTODUR KIT’s supplier landscape is driven by:

Composition of matter and dosage form patents on triptorelin pamoate and prolonged-release depot technology.
Manufacturing process patents tied to sustained-release microspheres/solid depot formation and sterile manufacturing.
Method-of-use and therapeutic indication patents for specific approved clinical uses.

Supplier concentration tends to increase when patents cover:

the exact prolonged-release formulation (not just the API),
the kit-specific configuration (what components are included and how they are assembled),
and/or manufacturing method constraints that require specialized capabilities.

What contract manufacturing steps exist for TRIPTODUR KIT, and who typically performs them?

A prolonged-release injectable kit generally requires multiple steps. Typical split-of-responsibility looks like:

Drug substance and drug product

Triptoerlin pamoate synthesis or procurement as bulk API or drug substance intermediate.
Prolonged-release formulation production (depot technology).
Sterile filling or sterile processing (depending on the product’s presentation).
Primary packaging and labeling.

Kit assembly

Assembly of the kit components into the final configuration used in clinical administration.
Secondary packaging, labeling to local language/requirements, and distribution readiness.

Quality release

Batch record review and QA release by the MAH or its authorized release unit.
Compliance with GDP, cold chain requirements if applicable, and country-specific pharmacovigilance distribution rules.

Which suppliers support TRIPTODUR KIT in the US, EU, UK, and other markets?

Supplier coverage varies by territory due to:

import authorization,
local marketing authorization holder structure,
and hospital distribution contracts.

Most operationally, procurement teams should request from candidates:

country-specific site of manufacture shown on labels,
GMP certificate for the relevant product and dosage form,
and whether the supplier provides “kit” versus only “drug product components.”

This avoids qualification failures during regulatory inspections or distributor audits.

What generic entry risks exist for TRIPTODUR KIT that could change the supplier base?

The supplier base can change when:

equivalent prolonged-release formulations are approved for the same clinical use,
or kits with substitutable injection configurations enter through regulatory pathways.

For supplier mapping, the most direct triggers are:

approvals of therapeutically equivalent alternatives in your target market,
and any settlement outcomes in kit-equivalent patent disputes (if any are filed in the jurisdiction).

When alternatives appear, procurement and distributors typically expand the bid set.

Supplier qualification checklist for TRIPTODUR KIT (depot injection kits)

For any potential supplier, qualification should confirm:

Kit manufacturer of record (or kit assembly site).
Sterile manufacturing and fill-finish responsibility (if applicable).
GMP compliance for prolonged-release depot technology.
Batch release location and QA contacts.
Stability program covering the full kit configuration.
GDP and cold chain controls, where used.
Regulatory submission alignment with the market’s labeled kit components.

Key Takeaways

TRIPTODUR KIT supply chains usually concentrate around a small set of roles: MAH sponsor supply, one or more contract manufacturing sites for DP, and a kit assembly/packaging supplier.
The highest supplier risk is the distinction between supplying the assembled kit versus supplying components that must be assembled elsewhere.
Supplier availability by territory depends on marketing authorization structure and import/distribution contracts.
Supplier qualification must verify the exact kit configuration, manufacturing site(s), and QA batch release responsibilities tied to the labeled product.

FAQs

1) Who is the market authorization holder for TRIPTODUR KIT in my target country?
The MAH is the practical procurement counterparty for supply continuity and batch release responsibility in-country.

2) What is the difference between a TRIPTODUR KIT supplier and a kit assembly contractor?
A supplier may provide assembled kits, while an assembly contractor may only assemble components under contract for the MAH or a local affiliate.

3) How do I verify the GMP site for the TRIPTODUR KIT I’m buying?
Use the labeled manufacturer/packager lines and obtain GMP documentation for the labeled dosage form and kit configuration.

4) Are TRIPTODUR KIT suppliers the same as tritporelin API suppliers?
Often not. API sourcing and depot formulation manufacturing can be separate contract systems.

5) What documentation do distributors require for prolonged-release injectable kits like TRIPTODUR?
Distributors typically require GDP compliance evidence, batch/expiry traceability, and confirmation that the kit is stored and transported per label conditions.

References (APA)

No sources were provided in the prompt, and none can be cited reliably for TRIPTODUR KIT supplier entities without risking fabrication.

Suppliers and packagers for TRIPTODUR KIT

TRIPTODUR KIT